Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract WMP8: Tenecteplase vs Alteplase: is Pro-Inflammatory and Procoagulant Response Any Different in Acute Ischemic Stroke?

View through CrossRef
Introduction: Thrombolysis in acute ischemic stroke (AIS) using Tenecteplase (TNK) is gaining popularity compared to Alteplase (ALT) for its practical advantages. At our center, we observed an improvement in clinical outcome in TNK treated patients compared to ALT. Hence, we aimed to study the pro-inflammatory and procoagulant responses post-thrombolysis and their contributory role in clinical outcome. Methods: This is a single-center retrospective study of ALT or TNK treated AIS patients admitted to a comprehensive stroke center over a 3-year period. Non-parametric tests were used to compare differences between the ALT and TNK cohorts. Peripheral blood indices, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), and mean platelet volume to platelet count ratio (MPV:PLT), were calculated. Their rise from pre-thrombolysis baseline during the first 48 hours was used to define a systemic inflammatory and procoagulant response. A p-value of <0.05 was considered statistically significant. Results: During the study period, 165 and 64 patients were treated with ALT and TNK respectively. The baseline demographics, vascular risk factors, and admission stroke severity were similar. Admission NLR, PLR, MLR, and MPV:PLT were not statistically different. Clinical outcome at 3 months assessed using median modified Rankin Scale (mRS) was better with TNK (2.0 [IQR, 1.0, 4.0] vs 3.0 [IQR, 2.0, 5.0]; p = 0.0007). Rise in NLR was significantly higher in the ALT cohort compared to TNK on day 1 (2.25 [IQR, 0.0, 5.77] vs. 0.49 [IQR, -0.48, 3.91], p = 0.01) and day 2 (1.58 [IQR, -0.09, 5.68] vs. 0.39 [IQR, -0.96, 2.91], p = 0.045). Similarly, MLR on day 2 in the ALT cohort (0.16 [IQR, 0.05, 0.49] vs. 0.12 [IQR, -0.05, 0.22], p = 0.038) and MPV:PLT on day 1 (0.61 [IQR, 0.16, 1.35] vs. 0.32 [IQR, 0.003, 0.68], p = 0.002) and day 2 (0.83 [IQR, -0.35, 1.90] vs. 0.36 [IQR, -0.12, 1.21], p = 0.004) were higher. Conclusions: Patients treated with TNK had better mRS scores compared to ALT in our study. This was associated with significantly less inflammatory and procoagulant response during the first 48 hours of AIS in the TNK group. The etiology for such an association is speculative and needs confirmation using more specific biomarkers.
Ovid Technologies (Wolters Kluwer Health)
Title: Abstract WMP8: Tenecteplase vs Alteplase: is Pro-Inflammatory and Procoagulant Response Any Different in Acute Ischemic Stroke?
Description:
Introduction: Thrombolysis in acute ischemic stroke (AIS) using Tenecteplase (TNK) is gaining popularity compared to Alteplase (ALT) for its practical advantages.
At our center, we observed an improvement in clinical outcome in TNK treated patients compared to ALT.
Hence, we aimed to study the pro-inflammatory and procoagulant responses post-thrombolysis and their contributory role in clinical outcome.
Methods: This is a single-center retrospective study of ALT or TNK treated AIS patients admitted to a comprehensive stroke center over a 3-year period.
Non-parametric tests were used to compare differences between the ALT and TNK cohorts.
Peripheral blood indices, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), monocyte to lymphocyte ratio (MLR), and mean platelet volume to platelet count ratio (MPV:PLT), were calculated.
Their rise from pre-thrombolysis baseline during the first 48 hours was used to define a systemic inflammatory and procoagulant response.
A p-value of <0.
05 was considered statistically significant.
Results: During the study period, 165 and 64 patients were treated with ALT and TNK respectively.
The baseline demographics, vascular risk factors, and admission stroke severity were similar.
Admission NLR, PLR, MLR, and MPV:PLT were not statistically different.
Clinical outcome at 3 months assessed using median modified Rankin Scale (mRS) was better with TNK (2.
0 [IQR, 1.
0, 4.
0] vs 3.
0 [IQR, 2.
0, 5.
0]; p = 0.
0007).
Rise in NLR was significantly higher in the ALT cohort compared to TNK on day 1 (2.
25 [IQR, 0.
0, 5.
77] vs.
0.
49 [IQR, -0.
48, 3.
91], p = 0.
01) and day 2 (1.
58 [IQR, -0.
09, 5.
68] vs.
0.
39 [IQR, -0.
96, 2.
91], p = 0.
045).
Similarly, MLR on day 2 in the ALT cohort (0.
16 [IQR, 0.
05, 0.
49] vs.
0.
12 [IQR, -0.
05, 0.
22], p = 0.
038) and MPV:PLT on day 1 (0.
61 [IQR, 0.
16, 1.
35] vs.
0.
32 [IQR, 0.
003, 0.
68], p = 0.
002) and day 2 (0.
83 [IQR, -0.
35, 1.
90] vs.
0.
36 [IQR, -0.
12, 1.
21], p = 0.
004) were higher.
Conclusions: Patients treated with TNK had better mRS scores compared to ALT in our study.
This was associated with significantly less inflammatory and procoagulant response during the first 48 hours of AIS in the TNK group.
The etiology for such an association is speculative and needs confirmation using more specific biomarkers.

Related Results

Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy
Safety and Efficacy Comparison of Tenecteplase and Alteplase for Clinically Suspected Large Vessel Occlusion Strokes without Thrombectomy
Introduction: Tenecteplase is a thrombolytic with higher fibrin affinity and is potentially better in clot lysis. A higher spontaneous recanalisation rate for large vessel occlusio...
Tenecteplase for Intravenous Thrombolysis of Ischemic Stroke: A Single MRI-based Comprehensive Stroke Center Experience
Tenecteplase for Intravenous Thrombolysis of Ischemic Stroke: A Single MRI-based Comprehensive Stroke Center Experience
Abstract Background: Tenecteplase is a tissue plasminogen activator with higher fibrin specificity compared with Alteplase. Accumulating data suggests that intravenous Tene...
CASE SERIES: EFFICACY OF THROMBOLYSIS USING INTRAVENOUS ALTEPLASE IN ACUTE ISCHEMIC STROKE WITH ONSET LESS THAN 6 HOURS (CODE STROKE)
CASE SERIES: EFFICACY OF THROMBOLYSIS USING INTRAVENOUS ALTEPLASE IN ACUTE ISCHEMIC STROKE WITH ONSET LESS THAN 6 HOURS (CODE STROKE)
Background: The gold standard therapy for acute ischemic stroke is timely reperfusion of ischemic brain tissue. Intravenous thrombolysis with tPA is the only proven medical therapy...
Efficacy and safety of tenecteplase versus alteplase in acute ischemic stroke: Evidence from a South Indian cohort
Efficacy and safety of tenecteplase versus alteplase in acute ischemic stroke: Evidence from a South Indian cohort
Background. Acute ischemic stroke (AIS) requires efficient thrombolytic therapy to re-establish vascular permeability and mitigate tissue damage. Alteplase and tenecteplase are pro...
Tenecteplase Thrombolysis in Posterior Circulation Stroke
Tenecteplase Thrombolysis in Posterior Circulation Stroke
One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mo...
Iranian stroke model-how to involve health policymakers
Iranian stroke model-how to involve health policymakers
Stroke in Iran, with more than 83 million population, is a leading cause of disability and mortality in adults. Stroke has higher incidence in Iran comparing the global situation a...
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
Comparative Characterization of Candidate Molecular Markers in Ischemic and Hemorrhagic Stroke
According to epidemiological studies, the leading cause of morbidity, disability and mortality are cerebrovascular diseases, in particular ischemic and hemorrhagic strokes. In rece...

Back to Top